Search results for "Drug administration"

showing 10 items of 393 documents

Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study

2015

Purpose Peripheral T-cell lymphomas (PTCLs) represent a diverse group of non-Hodgkin lymphomas with a poor prognosis and no accepted standard of care for patients with relapsed or refractory disease. This study evaluated the efficacy and tolerability of belinostat, a novel histone deacetylase inhibitor, as a single agent in relapsed or refractory PTCL. Patients and Methods Patients with confirmed PTCL who experienced progression after ≥ one prior therapy received belinostat 1,000 mg/m2 as daily 30-minute infusions on days 1 to 5 every 21 days. Central assessment of response used International Working Group criteria. Primary end point was overall response rate. Secondary end points included …

AdultMaleOncologyCancer Researchmedicine.medical_specialtymedicine.drug_classAntineoplastic AgentsKaplan-Meier EstimateHydroxamic AcidsDisease-Free SurvivalDrug Administration Schedulechemistry.chemical_compoundRefractoryInternal medicineClinical endpointHumansMedicineInfusions IntravenousAgedAged 80 and overSulfonamidesbusiness.industryHistone deacetylase inhibitorLymphoma T-Cell PeripheralORIGINAL REPORTSMiddle Agedmedicine.diseaseLymphomaSurgeryHistone Deacetylase InhibitorsClinical trialTreatment OutcomePrior TherapyOncologyTolerabilitychemistryDrug Resistance NeoplasmFemaleNeoplasm Recurrence LocalbusinessBelinostatJournal of Clinical Oncology
researchProduct

Chemoradiotherapy of Newly Diagnosed Glioblastoma With Intensified Temozolomide

2009

Purpose To evaluate the toxicity and efficacy of chemoradiotherapy with temozolomide (TMZ) administered in an intensified 1-week on/1-week off schedule plus indomethacin in patients with newly diagnosed glioblastoma. Patients and Methods A total of 41 adult patients (median Karnofsky performance status, 90%; median age, 56 years) were treated with preirradiation TMZ at 150 mg/m 2 (1 week on/1 week off), involved-field radiotherapy combined with concomitant low-dose TMZ (50 mg/m 2 ), maintenance TMZ starting at 150 mg/m 2 using a 1-week on/1-week off schedule, plus maintenance indomethacin (25 mg twice daily). Results The median follow-up interval was 21.7 months. Grade 4 hematologic toxicit…

AdultMaleOncologyCancer Researchmedicine.medical_specialtymedicine.medical_treatmentIndomethacinDisease-Free SurvivalDrug Administration ScheduleGermanyInternal medicineConfidence IntervalsTemozolomidemedicineHumansRadiology Nuclear Medicine and imagingProspective StudiesKarnofsky Performance StatusAntineoplastic Agents AlkylatingDNA Modification MethylasesSurvival rateAgedChemotherapyRadiationTemozolomideBrain Neoplasmsbusiness.industryTumor Suppressor ProteinsAnti-Inflammatory Agents Non-SteroidalDNA MethylationMiddle AgedCombined Modality TherapyConfidence intervalSurgeryDacarbazineSurvival RateRegimenDNA Repair EnzymesOncologyConcomitantToxicityFemaleGlioblastomabusinessChemoradiotherapyFollow-Up Studiesmedicine.drugInternational Journal of Radiation Oncology*Biology*Physics
researchProduct

Dose escalation vs. continued doses of paroxetine and maprotiline: a prospective study in depressed out-patients with inadequate treatment response

1997

In view of the fact that controlled prospective studies on the benefits of dose escalation of the selective serotonin re-uptake inhibitor (SSRI) paroxetine are lacking, we conducted a double-blind, randomized, parallel-group multicentre study designed to compare the possible benefits of dose escalation of paroxetine and maprotiline in patients suffering from major or minor depression according to modified Research Diagnostic Criteria (RDC) with inadequate treatment response. The study sample consisted of 544 out-patients with different degrees of severity of depression. Patients received either 20 mg paroxetine (n = 271) or 100 mg maprotiline (n = 273) for the first 3 weeks in a double-blin…

AdultMalePersonality InventoryResearch Diagnostic CriteriaDrug Administration Schedulelaw.inventionDouble-Blind MethodRandomized controlled triallawmedicineHumansProspective StudiesMaprotilineProspective cohort studyAdverse effectDepressive DisorderDose-Response Relationship DrugMiddle AgedParoxetineClinical trialParoxetinePsychiatry and Mental healthTreatment OutcomeMaprotilineAnesthesiaAntidepressive Agents Second-GenerationFemaleReuptake inhibitorPsychologymedicine.drugActa Psychiatrica Scandinavica
researchProduct

Chronology of panic and avoidance, age of onset in panic disorder, and prediction of treatment response. A report from the Cross-National Collaborati…

1991

The relevance of the chronology between panic disorder and avoidance behavior and of an early, medium or late onset of panic disorder was tested. Groups from the sample of the cross-national collaborative panic study (CNCPS) were compared for differences in basic characteristics and for the ability to predict treatment response. Patients who developed avoidance behavior before the full syndrome of panic disorder had less often a full agoraphobia but were not different in their response to treatment. Patients with an early onset of panic disorder suffered more often from agoraphobia. The treatment response was similar in the groups with early, medium or late onset of panic disorder. Neither …

AdultMalePersonality Testsmedicine.medical_specialtyImipramineLate onsetbehavioral disciplines and activitiesImipramineDrug Administration Schedulelaw.inventionRandomized controlled triallawmental disordersmedicineHumansPharmacology (medical)PsychiatryBiological PsychiatryAlprazolamGeneral NeurosciencePanic disorderAge FactorsPanicGeneral MedicineMiddle Agedmedicine.diseasePrognosisAnxiety DisordersPanichumanitiesPsychiatry and Mental healthNeuropsychology and Physiological PsychologyAlprazolamFemalemedicine.symptomAge of onsetPsychologyArousalmedicine.drugClinical psychologyAgoraphobiaEuropean archives of psychiatry and clinical neuroscience
researchProduct

Deep inspiration-induced changes in lung volume decrease with severity of asthma

2007

Summary We have previously reported that the magnitude of deep inspiration (DI)-induced bronchodilation is only slightly reduced in mild asthmatics, compared to healthy subjects. The aim of this study was to evaluate whether increased severity of asthma is associated with impairment in the ability of DI to induce changes in lung volume. Thirty-six consecutive asthmatics recruited from the Pulmonary and the Allergy Outpatient Clinics of the Institute of Respiratory Diseases of the University of Palermo were divided into 3 groups: Intermittent (I), Mild Persistent (MP) and Moderate–Severe (MS), based on GINA guidelines. Single dose methacholine (Mch) bronchoprovocations were performed in the …

AdultMalePulmonary and Respiratory MedicineAllergymedicine.medical_specialtyAdolescentVital CapacityBronchiSettore MED/10 - Malattie Dell'Apparato RespiratorioGastroenterologySeverity of Illness IndexBronchial Provocation TestsDrug Administration ScheduleLung inflationBronchoconstrictor Agents03 medical and health sciencesFEV1/FVC ratio0302 clinical medicineInternal medicineForced Expiratory VolumemedicineOutpatient clinicCorticosteroidsHumansLung volumesAlbuterol030212 general & internal medicineasthma deep inspiration lung functionMethacholine ChlorideAsthmaAgedMethacholinebusiness.industryRespiratory diseaseMiddle Agedmedicine.diseaseAsthma3. Good healthBronchodilator Agents030228 respiratory systemInhalationAnesthesiaSalbutamolMethacholineBronchodilationFemalebusinessmedicine.drugRespiratory Medicine
researchProduct

Adjustable maintenance dosing with budesonide/formoterol in a single inhaler provides effective asthma symptom control at a lower dose than fixed mai…

2004

Asthma guidelines suggest a stepwise approach to maintenance pharmacological treatment of persistent asthma until control is attained, and a 3 month review of the fixed maintenance dosing for step-up or step-down adjustment. This 12-week study compared the efficacy and safety of budesonide/formoterol in a single inhaler (Symbicort Turbuhaler 160/4.5 or 80/4.5 microg) given as adjustable maintenance or fixed maintenance dosing. Patients (n = 2358) were randomised to budesonide/formoterol fixed maintenance dosing (two inhalations bid) or adjustable maintenance dosing (two inhalation bid; stepping up to four inhalations bid if asthma worsened for a maximum of 14 days; stepping down to two inha…

AdultMalePulmonary and Respiratory MedicineBudesonidemedicine.drug_classDrug Administration ScheduleFormoterol FumarateBronchodilatormedicineHumansPharmacology (medical)DosingBudesonideathma; therapy; guidelinesAsthmaDose-Response Relationship DrugInhalationbusiness.industryNebulizers and VaporizersInhalerBiochemistry (medical)medicine.diseaseAsthmaBronchodilator Agentsrespiratory tract diseasesTreatment OutcomeBudesonide/formoterolEthanolaminesAnesthesiaDrug Therapy CombinationFemaleFormoterolbusinessmedicine.drugPulmonary Pharmacology & Therapeutics
researchProduct

Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: The BRIGHT study

2014

Summary Introduction QVA149 is a novel, inhaled, once-daily dual bronchodilator containing a fixed-dose combination of the long-acting β 2 -agonist indacaterol and the long-acting muscarinic antagonist glycopyrronium (NVA237), for the treatment of chronic obstructive pulmonary disease (COPD). This study evaluated the effects of QVA149 on exercise tolerance, hyperinflation, lung function and lung volumes versus placebo and tiotropium. Methods Patients with moderate-to-severe COPD were randomized to QVA149 110/50 μg, placebo or tiotropium 18 μg once daily in a blinded, 3-period crossover study for 3 weeks. The primary endpoint was exercise endurance time at Day 21 for QVA149 versus placebo. R…

AdultMalePulmonary and Respiratory Medicinemedicine.drug_classVital CapacityScopolamine DerivativesHyperinflationQuinolonesPlaceboDrug Administration SchedulePulmonary Disease Chronic ObstructiveFunctional residual capacityDouble-Blind MethodForced Expiratory VolumeBronchodilatormedicineClinical endpointHumansLung volumesTiotropium BromideExerciseAgedCOPDCross-Over StudiesExercise Tolerancebusiness.industryChronic obstructive pulmonary diseaseTiotropiumQVA149Middle Agedmedicine.diseaseGlycopyrrolateCrossover studyBronchodilator Agentsrespiratory tract diseasesDrug CombinationsTreatment OutcomeSpirometryAnesthesiaIndansIndacaterolFemaleLung Volume Measurementsbusinessmedicine.drugRespiratory Medicine
researchProduct

Serotonergic modulation of response inhibition and re-engagement? Results of a study in healthy human volunteers

2010

Objective Cognitive functions dependent on the prefrontal cortex, such as the ability to suppress behavior (response inhibition) and initiate a new one (response re-engagement) is important in the activities of daily life. Central serotonin (5-HT) function is thought to be a critical component of these cognitive functions. In recent studies, 5-HT failed to affect stop-signal reaction time (SSRT), a fundamental process in behavioral inhibition. We were interested if response inhibition and re-engagement are influenced through central 5-HT activity as mediated via the 5-HT transporter. Methods Here, using a stop-change task, we investigated the effects of acute and repeated treatment with 10 …

AdultMaleSerotoninCitalopramCitalopramSerotonergicDrug Administration ScheduleDevelopmental psychologyDouble-Blind MethodReaction TimemedicineHumansEscitalopramPharmacology (medical)Prefrontal cortex5-HT receptorCross-Over StudiesDose-Response Relationship DrugCognitionInhibition PsychologicalPsychiatry and Mental healthNeurologyNeurology (clinical)SerotoninReuptake inhibitorPsychologyNeuroscienceSelective Serotonin Reuptake Inhibitorsmedicine.drugHuman Psychopharmacology: Clinical and Experimental
researchProduct

Loss of the preconditioning effect of rosuvastatin during sustained therapy: a human in vivo study

2011

Studies have demonstrated that the acute administration of 3-hydroxy-3 methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors has protective effects in the setting of ischemia-reperfusion (IR). Previously, we demonstrated that a single dose of rosuvastatin prevented IR-induced endothelial dysfunction in humans through a cyclooxygenase-2-dependent mechanism. Whether the chronic administration of HMG-CoA reductase inhibitors provides similar protection remains controversial and is unknown in humans. Eighteen male volunteers were randomized to receive a single dose of rosuvastatin (20 mg) or placebo. Twenty-four hours later, endothelium-dependent, radial artery flow-mediated dilation (FMD) w…

AdultMaleTime FactorsAdolescentEndotheliumPhysiologyCoenzyme AHyperemiaPharmacologyReductaseDrug Administration ScheduleYoung Adultchemistry.chemical_compoundDouble-Blind MethodIschemiaIn vivoPhysiology (medical)medicineHumansRosuvastatinRosuvastatin CalciumOntarioAnalysis of VarianceSulfonamidesCyclooxygenase 2 Inhibitorsbiologybusiness.industryFluorobenzenesVasodilationRosuvastatin CalciumPyrimidinesmedicine.anatomical_structurechemistryCelecoxibRegional Blood FlowReperfusion InjuryRadial ArteryHMG-CoA reductasebiology.proteinCelecoxibPyrazolesHydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessBlood Flow Velocitymedicine.drugAmerican Journal of Physiology-Heart and Circulatory Physiology
researchProduct

Opioid Plasma Concentrations during a Switch from Transdermal Fentanyl to Methadone

2007

Opioid switching is often used to improve the opioid response in patients with cancer experiencing poor analgesia or adverse effects. When switching between drugs with delayed effect because of pharmacokinetics or type of delivery, concerns exist about the correct timing of introducing the second drug after stopping the previous one. The aim of this study was to assess plasmatic changes of fentanyl and methadone underlying the clinical events occurring during opioid switching. Eighteen patients with cancer receiving transdermal fentanyl with uncontrolled pain and/or moderate to severe opioid adverse effects, were switched to oral methadone using an initial fixed ratio of 1:20. Fentanyl patc…

AdultMaleTime FactorsPalliative careAdministration Cutaneousmethadone.Drug Administration ScheduleFentanylPharmacokineticsNeoplasmsHumansMedicineAdverse effectGeneral NursingAgedPain MeasurementTransdermalbusiness.industrywitchingPalliative CareOpioid plasma concentrationGeneral MedicineMiddle Agedtransdermal fentanylPain IntractableAnalgesics OpioidFentanylTreatment OutcomeAnesthesiology and Pain MedicineOpioidBasal (medicine)AnesthesiaFemalebusinessMethadonemedicine.drugMethadoneJournal of Palliative Medicine
researchProduct